Timothy Eugene Sullivan - 16 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
16 Jan 2024
Net transactions value
+$2,140,221
Form type
4
Filing time
17 Jan 2024, 16:36:16 UTC
Previous filing
01 Dec 2023
Next filing
23 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +23,748 +31% $0.000000 101,461 16 Jan 2024 Direct F1
transaction APLS Common Stock Sale $149,317 -2,235 -2.2% $66.81 99,226 16 Jan 2024 Direct F2
holding APLS Common Stock 56,232 16 Jan 2024 The Timothy E Sullivan Irrevocable Trust of 2023 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $2,289,538 +34,533 $66.30 34,533 16 Jan 2024 Common Stock 34,533 $66.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
F3 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F4 This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.